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The segmental premature aging disease Hutchinson-
Gilford Progeria syndrome (HGPS) is caused by
a truncated and farnesylated form of Lamin A called
progerin. HGPS affects mesenchymal lineages,
including the skeletal system, dermis, and vascular
smooth muscle (VSMC). To understand the under-
lying molecular pathology of HGPS, we derived
induced pluripotent stem cells (iPSCs) from HGPS
dermal fibroblasts. The iPSCs were differentiated
into neural progenitors, endothelial cells, fibroblasts,
VSMCs, and mesenchymal stem cells (MSCs). Pro-
gerin levels were highest in MSCs, VSMCs, and fibro-
blasts, in that order, with these lineages displaying
increased DNA damage, nuclear abnormalities, and
HGPS-VSMC accumulating numerous calponin-
staining inclusion bodies. Both HGPS-MSC and
-VSMC viability was compromised by stress and
hypoxia in vitro and in vivo (MSC). Because MSCs
reside in low oxygen niches in vivo, we propose
that, in HGPS, this causes additional depletion of
theMSC pool responsible for replacing differentiated
cells lost to progerin toxicity.
INTRODUCTION
Hutchinson-Gilford Progeria syndrome (HGPS) is a rare congen-
ital disease that may cause some aspects of premature aging in
children (Hennekam, 2006). Afflicted individuals generally die in
their early teens due to myocardial infarction or stroke, but it is
the wizened facial features and wasted bodies that have made
this harrowing condition familiar to the population at large. The
disease progression displays many symptoms of normal aging,
such as severe growth retardation, alopecia, loss of subcuta-
neous fat, and progressive atherosclerosis, although other
symptoms associated with aging such as neural degeneration,
diabetes, malignancies, and cataracts are absent (Ackermanand Gilbert-Barness, 2002; Gordon et al., 2007; Merideth et al.,
2008). This disease, which seems to affect mainly mesenchymal
lineages, is caused by an autosomal dominant mutation in the
LMNA gene (De Sandre-Giovannoli et al., 2003; Burke and Stew-
art, 2006; Capell and Collins, 2006). The most common (in 80%–
90% of cases) mutation is a C-T transition at position 1824 in
exon 11 that creates an efficient alternative splice donor site.
This leads to the production of a truncated lamin A protein
(progerin) with an internal deletion of 50 amino acids in the
C-terminal globular domain. As a result of this mutation, pro-
gerin, but not mature lamin A, retains a C-terminal farnesyl tail
that is normally only transiently present in the Lamin A precursor.
Farnesyl retention is widely thought to underlie the intracellular
disruption associated with progerin, although the exact roles of
the farnesyl group and the deletion in the etiology of the disease
are controversial (Yang et al., 2008).
The cell type-specific pathologies in HGPS have been attrib-
uted to a variety of causes, including progerin-mediated stem
cell pool exhaustion (Halaschek-Wiener and Brooks-Wilson,
2007), mesenchymal lineage differentiation defects (Scaffidi
and Misteli, 2008), a diminished DNA-damage-repair response
(Musich and Zou, 2009), and nuclear fragility in mechanically
stressed cells such as cardiomyocytes (Verstraeten et al.,
2008). Interestingly, the same aberrant splicing event may also
occur at much lower levels in normal cells (Scaffidi and Misteli,
2006). Although low progerin RNA levels may not increase with
age, several reports have suggested that progerin protein levels
do increase, (McClintock et al., 2007; Scaffidi and Misteli, 2006),
possibly reflecting a low turnover of the protein or an age-related
inability to remove cells with high progerin loads. This has led to
speculation that studies on progeria may provide insight into the
normal human aging process.
Due to the rarity and juvenile mortality of this disease, biopsy
and autopsy analysis has been limited, although pronounced
vascular smooth muscle loss and artherosclerosis appear to
be critical factors contributing to the death of patients (Stehbens
et al., 2001; Olive et al., 2010). Much of the information relating to
the pathophysiology of HGPS has come from studies on patient-
derived skin fibroblasts, wild-type and mutant lamin A overex-
pression in established cell lines (Cao et al., 2007; Goldman
et al., 2004), and the development of various mouse models inCell Stem Cell 8, 31–45, January 7, 2011 ª2011 Elsevier Inc. 31
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Figure 1. Generation of Patient-Specific iPSCs
(A) HGPS patient fibroblasts AG11498 (PG1) and AG06297 (PG2) were obtained from the Coriell Institute, and two unaffected HGPS parental fibrolast lines,
AG03512 (N1) and AG06299 (N2), were used as controls. Immunofluorescence microscopy of fibroblast cells using an antibody specifically recognizing mutant
LMNA (progerin) shows specific expression of progerin in HGPS patient fibroblasts, but not controls. Immunostaining with JOL2 antibody recognizing human
LMNA/C (right panels) shows increasing nuclear deformation (arrows) in HGPS fibroblasts undergoing extended passaging from p15 to p26. The percentage
of cells showing aberrant nuclei is indicated for respective passages. Scale bar, 20 mm.
(B) Progerin expression in donor fibroblasts. Western blot analysis of fibroblast lysates using the JOL2 antibody recognizes both human LMNA and -C.
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Progeria iPSC Model Reveals MSC and VSMC Defectswhich the lamin A gene is deleted, mutated, and/or overex-
pressed (Mounkes et al., 2003; Yang et al., 2005; Varga et al.,
2006; Sagelius et al., 2008; Hernandez et al., 2010). The use of
mouse models has been particularly informative; however, no
one mouse model recapitulates all the symptoms seen in the
human disease.
Recently, a number of human disease models have been
established by the transcription-factor-mediated reprogram-
ming of somatic cells taken from patients with Lou Gehrig’s
disease (Dimos et al., 2008), spinal muscular atrophy (Ebert
et al., 2009), familial dysautonomia (Lee et al., 2009), and dysker-
atosis congenita (Agarwal et al., 2010). In all cases, the reprog-
rammed cells (induced pluripotent stem cells [iPSCs]) were
used to derive cell types that, in vivo, display a distinctive
disease phenotype. The underlying hope behind these studies
is that a disease pathology will emerge in a relatively short time
(compared to disease progression in vivo) and generate insight
into early disease pathophysiology, as well as providing cell
types for drug screening and discovery.
Here, we describe an iPSC model of HGPS. iPSC lines were
made from patient-derived fibroblasts and differentiated into
mesenchymal and nonmesenchymal lineages to analyze the
impact of progerin on the functional properties of the different
cell types. We find that progerin levels are highest in mesen-
chymal stem cells, VSMCs, and fibroblasts, and lowest in the
neural progenitors. Progerin expressing VSMCs and MSCs,
but not controls, are sensitive to hypoxia, and HGPS-MSCs fail
to mediate circulatory restoration in a murine hind limb recovery
model. We speculate that one significant cause of progeria
pathology is a shortage of MSCs needed for tissue replacement,
and this shortage is exacerbated by a loss of specific differenti-
ated types due to progerin. Our experiments support the hypoth-
esis that the MSC pool becomes exhausted due to replicative
overload in HGPS patients (Halaschek-Wiener and Brooks-Wil-
son, 2007), which is compounded by a parallel depletion due
to progerin-induced sensitivity of the stem cells to their niche
conditions.
RESULTS
Generation of HGPS-iPSCs
Skin-derived fibroblast cultures from two HGPS patients
(AG11498 [PG1], AG06297 [PG2]) and two HGPS parents
(AG03512 [N1], AG06299 [N2]) were obtained from the Coriell
Institute. Both patient genomes contain the typical C-T mutation
of LMNA gene at position 1824 of exon 11. The mutant protein,
progerin, was detected exclusively in HGPS fibroblasts by
western analysis and immunofluorescence using a progerin-
specific antibody (Figure 1). Nuclear membrane deformation(C) Reduced reprogramming efficiency of HGPS fibroblasts. Efficiencies were c
transduction of 105 HGPS (PG1, PG2) or control (N1, N2) fibroblasts by retroviru
passage (p25–p30) HGPS fibroblasts.
(D) Immunohistology of iPSC clones. Phase contrast (row 1) with alkaline phospha
rows) for the following pluripotent markers: OCT4, SOX2, NANOG, SSEA-4, and
(E) Cluster analysis ofmicroarray data fromHGPS fibroblast (PG1, PG2), control fib
N2-iPS-1) and human ESC (HES3, H9) RNA. The Pearson correlation coefficient (
expression level of all transcripts. Hierarchical cluster analysis was carried out w
See also Figures S1 and S2 for characterization of iPSCs.‘‘blebbing’’ was seen in approximately 20%–30% HGPS fibro-
blasts at p15-20, in contrast to 3%–11% in normal fibroblast cells
at similar passage. This increased to 60%–70% in HGPS fibro-
blasts by p25-30, withmoremodest increases seen in the control
fibroblasts. PG1, PG2, and N2 fibroblasts displayed normal
karyotypes. However, in N1 fibroblasts, 55% of cells had an
abnormal karyotype with trisomy 7. We reprogrammed the four
fibroblast lines by retrovirus infection of cells at p15-20 using
the ‘‘Yamanaka’’ factor cocktail: OCT4, SOX2, KLF4, and C-
MYC. Infected fibroblasts were cultured on amurine feeder layer
with 0.5 mM valproic acid in human ESCmedium. iPSC colonies
were observed at 2 to 3weeks and picked between 3 to 4 weeks.
Though the efficiency of reprogramming ofHGPSfibroblastswas
4-fold lower than parental control fibroblasts (Figure 1C), all the
colonies picked were expanded and displayed morphologies
indistinguishable from human ESCs (Figure 1D): no colonies
were obtained from the two HGPS fibroblast cultures at late
passage (p26). We attribute this failure to the onset of senes-
cence observed in these cultures beginning at p22 since efficient
iPSC generation is associated with a cell’s proliferative potential
(Hanna et al., 2009). Five to ten colonieswere picked to represent
each patient or control, and for the N1-iPSC, about 50% of the
colonies displayed a normal karyotype.
Characterization of iPSCs
Exogenous expression of the four reprogramming factors was
screened for by RT-PCR in all the iPSC clones. No transgenic
transcripts were found in any clone (Figure S1A available online).
Two clones from each patient or control (given the suffix iPSC-1
or iPSC-2) each with a normal karyotype (Figure S1B) were
selected for further characterization. DNA sequencing revealed
HGPS-iPSC but no control clones had the C-T mutation of the
LMNA gene (Figure S1C). All clones express the pluripotent
markers OCT4, SOX2, NANOG, SSEA4, and TRA1-80, as deter-
mined by immunocytochemistry (Figure 1D). In addition, all iPSC
lines showed reactivation of three endogenous pluripotency-
related genes with similar level of expression as seen in hESCs
(Figure S2A). As expected for hiPSCs, theOCT4 promoter region
in all iPSCs (and hESC3) was hypomethylated in contrast to its
hypermethylated state in the parental fibroblasts (Figure S2B).
To test the pluripotency of iPSCs, teratoma assays were per-
formed in SCID mice. All the clones developed teratomas
comprised of tissues from all three germ layers (Figure S2C).
The transcriptomes of two independently derived sister clones
from each hiPSC genotype were compared to that in two
different hESC lines (hESC3 and H9) by microarray analysis on
24,000 gene Illumina chips. Clustering analysis revealed a high
degree of similarity (r = 0.99) between the reprogrammed
HGPS-iPSCs (PG1-iPSCs, PG2-iPSCs) and parental controlalculated as number of alkaline phosphatase positive colonies at day 21 after
ses carrying OSKM. *p < 0.01, n = 3. No iPS colonies were obtained for late
tase (AP) staining (inset) and immunofluorescence staining of iPSCs (remaining
Tra-1-81. Two iPS clones were analyzed for each line.
roblast (N1, N2), HGPS-iPSC (PG1-iPS-1, PG2-iPS-1), control iPSC (N1-iPS-1,
PCC) was calculated for each pair of samples (see Table S1) using the relative
ith PCC as the distance measurement using Illumina GenomeStudio software.
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Figure 2. Expression of LMNA and Progerin Is Suppressed in iPSCs
(A) Immunofluorescence staining of LMNA/C on human ESC line HES3 and
HGPS iPSCs (PG1) with JOL2 antibody shows LMNA/C expression in differen-
tiated cells lining the edge of colonies. Costaining of LMNA/C with SOX2
shows suppressed expression of LMNA/C in pluripotent iPSCs. Scale bar,
50 mm.
(B) qPCR of LMNA and progerin expression in HGPS-iPSCs after colony
dissection. Most expression was seen at the colony edges where differentia-
tion was occurring.
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Progeria iPSC Model Reveals MSC and VSMC DefectsiPSC (N1-iPSCs, N2-iPSCs) that clustered with the hESC group
(r = 0.99). The three groups were distant from the HGPS and
control fibroblasts (r = 0.82) (Figure 1E, Table S1). The above
data indicate that, despite the presence of progerin in the
nucleus, somatic cells from HGPS patients can be reprog-
rammed into iPSCs with characteristics that are highly similar
to embryo-derived human ESCs.
LaminA/C and Progerin Expression Are Silenced
by Reprograming
Lamins A and C are transcribed from the same promoter and
share the first 566 amino acids. Undifferentiated mESCs and
hESCs do not express LMNA transcripts (Constantinescu
et al., 2006). Immunofluorescent analysis of the iPSC colonies re-
vealed that LMNA proteins were expressed in differentiated cells
at the edge of the colony, whereas the bulk of the colony stained
for the pluripotent marker SOX2 (Figure 2A). No specific staining
for progerin was detected in any region. Quantitative RT-PCR
analysis confirmed the presence of LMNA transcripts but
showed progerin transcripts present at lower levels. Colony
dissection indicated that the majority of these transcripts were
at the rim of the colonies (Figure 2B). In addition, RNA levels of
LMNA and progerin expression in intact HGPS-iPSC colonies
were less than 10% of those present in fibroblasts (Figure 3A).
These data demonstrate that LMNA expression in patient and
control fibroblasts was suppressed by reprogramming.
Differentiation of iPSCs
Clinical and autopsy data indicate that in HGPS, the main line-
ages affected are mesenchymal in origin with neural lineages
seemingly unaffected (McClintock et al., 2006; Merideth et al.,
2008). Since tissue samples from HGPS patients are extremely
rare, we used existing or modified protocols to derive MSC,
neural, and other candidate lineages for further examination.
LMNA and Progerin Are Re-expressed during iPSC
Differentiation
Differentiation of the HGPS-iPSC clones always resulted in
expression of lamins A, C, and progerin. We quantified lamin A
and C expression by both western and real-time RT-PCR anal-
ysis (Figures 3A and 3B). Progerin levels were highest in iPSC-
derived mesenchymal stem cells (MSCs), followed by vascular
smooth muscle cells (VSMCs), fibroblast, and endothelial cells,
in that order. Neural progenitors consistently showed the lowest
levels. Interestingly, we observed a 3- to 5-fold increase in
progerin levels over prolonged culture for iPSC-MSCs (Fig-
ure 3C), whereas in only one of the two HGPS-iPSC fibroblast
lines was an increase noted (data not shown). A similar inconsis-
tency in progerin accumulation, with passage number in patient
fibroblasts, was previously reported (Goldman et al., 2004;
Verstraeten et al., 2008). Overall, our observations are consistent
with skin biopsy data in finding significant presence of progerin in
endothelial and fibroblast lineages.
Impact of the HGPS Mutation on Fibroblast, Neural
Progenitor, Endothelial, and MSC Functions under
Normal Culture Conditions
Extended culture of HGPS and control fibroblasts revealed an
accumulation of abnormal nuclear morphologies (Bridger and34 Cell Stem Cell 8, 31–45, January 7, 2011 ª2011 Elsevier Inc.Kill, 2004). We obtained fibroblasts by FACS sorting of Thy1+
cells formed during differentiation of the iPSC lines. The purified
cells expressed prolyl 4-hydroxylase and displayed a similar
surface marker profile to parental fibroblasts—high in CD29,
CD44, and CD90 (Thy1) and low in CD106 (Figure 4A and Fig-
ure S3A). As with the HGPS-iPSC fibroblasts, we found
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Figure 3. Lamin A/C Expression in iPSC-Derived Fibroblasts, Endothelial Cells, Neural Progenitor Cells, VSMCs, and MSCs
(A) Relative Lamin A and progerin expression in iPSC differentiated samples by RT-PCR using Taqman probes. LMNA and progerin expression were each set as
100% for PG1 samples. Commercially available cell lines were used as references for each lineage: (1) N1 fibroblast p10, (2) PG1 fibroblast p10, (3) HESC3 p83, (4)
N1-iPSC-1p11, (5) PG1-iPSC-1 p13, (6)N1-iPSC-fibroblast p10, (7) PG1-iPSC-fibroblast p10, (8) N1-iPSC-VSMCp3, (9) PG1-iPSC-VSMCp3, (10) ReNcell human
fetal neural stem cell line, (11) N1-iPSC-neural p5, (12) PG1-iPSC-neural p5, (13) human umbilical vein endothelial cell line HUVEC p5, (14) N1-iPSC-endo p5, (15)
PG1-iPSC-endo p6, (16) human adult bone-marrow MSC p5, (17) N1-iPSC-MSC p6, and (18) PG1-iPSC-MSC p6. Data were normalized to GAPDH expression.
(B) Quantitative analysis of LMNA and progerin by western blot. Twenty micrograms of total protein extracts were loaded, and protein expression was quan-
titatively analyzed with the Odyssey infrared imaging system. Values represent relative densitometry normalized to GAPDH. The passage number of each
sample is indicated. The picture is combination of three separate blots which contained N1 and PG1 fibroblast lysates in each blot as the internal control.
(C) Accumulation of progerin in HGPS-iPSC-MSCs during extended passaging. Quantitative western blot shows progerin protein accumulation in two different
patient-derived HGPS-iPSC-MSCs.
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Progeria iPSC Model Reveals MSC and VSMC Defectsincreased nuclear dysmorphology, DNA damage (% nuclei with
3 or more foci staining for g-H2AX), and mislocalization of the
nuclear protein, LAP2, in progerin-expressing lines (Figure 4A).
Progerin accumulation was heterogeneous in the HGPS popula-
tions, and loss of LAP2 from the nuclei was more apparent in
nuclei displaying higher progerin levels and more pronounced
dysmorphology (Figure 4A, arrows). These results are similar to
those for HGPS patient fibroblasts after extended culture (Scaf-
fidi and Misteli, 2006).
Neither increased DNA-damage foci nor nuclear dysmorphol-
ogies were observed in iPSC-derived neural progenitors and
endothelial cells (Figures 4B and 4C). Neural progenitors were
propagated by neurosphere culture and characterized by nestin,
vimentin, and Ki67 staining (Figure 4B). Endothelial cultures were
CD31+ve/CD43ve, stained for VE-cadherin (Figure 4C) and were
also positive for CD31, VE-cadherin, C-KIT, and KDR transcripts
(Figure S3B). Neural progenitors made from different hESC or
iPSC lines at passages 7–10 were differentiated mainly into
Tuj-1+ve neurons (Figure 4B), although some GFAP-staining glial
cells were detected (data not shown). No differences were
observed between HGPS and normal neurospheres in growth
or neuronal differentiation. Both HGPS and control iPSC-derived
endothelial cells formed lattice-like vessel structures on Matrigel
(Figure 4C), a characteristic feature of endothelial cells. HGPS-
iPSC endothelial cells also displayed a normal lipid uptake func-
tion (Figure 4C).
MSCs were prepared from iPSC-derived EBs and were char-
acterized by FACS analysis as negative or low for the surface
markers of CD24, CD31, and CD34 and positive for CD29,
CD44, CD73, CD105, and CD166 (Figure S3C). Cluster analysis
of microarray data indicated that the iPSC-MSCs were more
closely related to hESC-derived and fetal bone marrow-derived
MSCs than adult bone marrow MSCs (Figure S3D).
MSCs differentiate into osteogenic, chondrogenic, and adipo-
genic lineages in vitro when provided with appropriate growth
conditions. All three lineages were formed from all the HGPS-
and control-iPSC-MSC lines (Figures 4D and 4E). Under
extended culture, the HGPS-MSCs showed considerable
nuclear lobulation that correlated with increasing levels of pro-Figure 4. Characterization of iPSC-Derived Fibroblast-like Cells, Endo
(A) Differentiation of iPSCs into fibroblast-like cells. Left panel: phase contrast pic
bodies against P4H, fibroblasts (D7-FIB), LMNA and H2AX. Right panel, Progeri
zation of LAP2 and progerin by immunostaining showed increased number of bleb
The percentage of cells showing aberrant phenotypes is indicated. The parental
(B) Characterization of iPS-derived neural progenitor cells. Immunostaining show
progenitor markers Ki67, nestin and vimentin and were able to differentiate into ne
Progerin and H2AX staining (green fluorescence) is rarely detected. The percenta
color. Scale bar, 50 mm.
(C) Differentiation of iPSCs into endothelial cells. Phase contrast pictures showing
specific markers, CD31 and VE-Cadherin. The percentage of cells showing aberra
of Dil-AC-LDL uptake of iPSC-derived endothelial cells. Scale bar, 20 mm.
(D) Differentiation of MSCs into bone, cartilage, and adipocyte. Bone marrow MS
teogenesis, adipogenesis, and chondrogenesis. Oil red, Safranin-O, and Alizarin
glycosaminoglycans (cartilage), and mineralization (bone), respectively.
(E) Semiquantitative analysis of adipogenesis and osteogenesis of MSCs. Oil red O
ing was semiquantitatively analyzed at 405 nm using a plate reader. Values repr
(F) Progerin accumulation leads to aberrant expression of LAP2 in late passageMS
number of blebbing nuclei associated with mislocalization of LAP2 in HGPS-MSC
is associated with mislocalization of LAP2. The percentage of cells showing abn
See also Figure S3 and Tables S1–S3 for further characterization of iPSC-derivegerin. The high percentage of nuclear malformation was accom-
panied by mislocalization of LAP2 (Figure 4F). A significant
increase in nuclei-containing DNA damage foci was also
observed in late passage HGPS-MSCs (Figure 4F).
VSMC were obtained from iPSC derived MSCs by treatment
with a combination of SPC and TGFb1 (Jeon et al., 2006). After
3 weeks of induction, 50%–60% cells showed specific VSMC
marker expression of a-smooth muscle actin, calponin 1, and
smooth muscle myosin heavy chain (Figure 5A) with the VSMC
lineage marker transcripts being confirmed by RT-PCR (Fig-
ure 5B). The VSMCs displayed a characteristic spindle-like
morphology and were induced to contract by carbachol admin-
istration (Figure 5C), supporting their VSMC identity. Like fibro-
blasts and MSCs, the HGPS-VSMCs displayed nuclear defor-
mations, LAP2 mislocalization, and increased DNA damage on
culture (Figure 5D). We also noticed that many, though not all,
the calponin 1-staining HGPS-VSMC cells had vesicular-like cal-
ponin 1 inclusions (Figure 5A), which were absent in control and
N-VSMCs. Although calponin decorates the filamentous actin
cytoskeleton, we observed no costaining of actin with these
bodies.
Patient iPSC-Derived VSMCs and MSCs Show
Functional Defects under Stress
Of the five lineages we derived, two (HGPS-iPSC-derived
VSMCs and MSCs) seem most adversely affected by progres-
sive culture under normoxic conditions. This might reflect the
higher levels of progerin these cell types appear to accumulate,
although fibroblasts levels are only slightly lower (Figure 3B). We
investigated whether other functional properties of these cells
were impaired.
VSMCs were subjected to three different conditions of stress:
hypoxia with substratum deprivation, hypoxia alone, and recur-
rent electrical stimulation. When HGPS-VSMCs were immersed
under mineral oil for 4 to 5 hr (substratum deprivation/hypoxia),
their survival was more than halved (Figure 6A). Hypoxia (2%
O2) for 3 days also increased senescence in HGPS-VSMCs,
shown by b-galactosidase staining (5.1% to 38.5%, Figure 6B).
To mimic the mechanical stresses endured by VSMCs in vivothelial Cells, Neural Progenitor Cells, and MSCs
tures and immunofluorescence staining of iPSC derived fibroblasts using anti-
n accumulation leads to aberrant expression of LAP2 in fibroblasts. Co-locali-
bed nuclei associated with mis-localization of LAP2 (arrows) in iPSC-fibroblast.
fibroblast N1 (03512) was used as a control. Scale bar, 15 mm.
ed that both HGPS and control iPSC-derived neurospheres expressed neural
urons with expression of bIII-tubulin (TuJ1) upon withdrawal of growth factors.
ge of cells showing aberrant phenotypes is indicated. DAPI stains nuclei a blue
the endothelial morphology and immunofluorescence staining with endothelial
nt phenotypes and DNA damage is indicated. Lower panels show live imaging
Cs, HGPS-iPSC-MSCs, and control-iPSC-MSCs were induced to undergo os-
red were used for staining of lipid oil droplet (adipocyte), proteogylcans and
was eluted with isopropanol and measured OD at l500 nm. Alizarin red stain-
esent mean ± SEM from three replicates.
Cs. Colocalization of LAP2 and progerin by immunostaining showed increased
s from p10 to p17. Nuclear blebbing with strong expression of progerin (arrows)
ormal phenotypes is indicated. Scale bar, 15 mm.
d lineages.
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Figure 5. Characterization of iPSC-Derived Vascular Smooth Muscle Cells
(A) Immunostaining of vascular smooth muscle cells (VSMCs) showed expression of a-smooth muscle actin (a-SMA), calponin, and VSMC exclusive marker
smooth muscle myosin heavy chain (SM-MHC). Lower panel shows colocalization of F-actin (phalloidin) with calponin. Scale bar, 15 mm.
(B) RT-PCR analysis of VSMC-specific contractile protein transcripts, a-SMA, calponin, smoothelin-B, h-caldesmon, and SMa-22. Neural cell line ReNcell was
used as control.
(C) Induction of contraction by carbachol treatment. Phase contrast image shows contraction of VSMCs under carbachol (1 3 105M) treatment for 1 hr (right
panel).
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Progeria iPSC Model Reveals MSC and VSMC Defectsdue to pulsatile circulation, repeated contraction of VSMCs was
chronically induced with electrical pulses (40V/cm, 1Hz) for
3 days. We observed an increase in nuclear dysmorphology
and accelerated senescence in both HGPS-VSMC and
N-VSMCs, although the effect was significantly greater with
the HGPS-VSMCs (Figure 6C).
Although the exact roles of MSCs in vivo are unclear, human
MSCs from bone marrow (Li et al., 2009) or from human embry-
onic stem cells (Lian et al., 2010) significantly improve vascular
circulation after their transplantation into the ischemic hind limbs
of immunocompromised mice. As a measure of their capacity to
effect such improvement, we tested parental control (N-MSC)-
and HGPS-iPSC-derived MSCs (HGPS-MSC) to protect against
ischemia in this mouse model. Mouse limb ischemia was
induced by ligation of the femoral artery and its branches in the
left hind-limb of SCID mice. The MSCs were transplanted by
intramuscular injection into the left hind-limb immediately after
ligation. After 28 days of transplantation, the culture medium-in-
jected group (vehicle group) displayed severe necrosis of the
ischemic limbs leading to limb loss (87.5%; Figure 7A). In the
15 mice given an N-MSC injection, limb loss was only 20%.
Most of the ischemic limbswere fully rescued (60%) or displayed
moderate necrosis from knee to toe. However, in the 15 mice
given HGPS-MSCs, rescue of ischemic limb occurred in only
one mouse (6.7%). Most mice suffered limb loss (60%), which
is significantly different from that seen with N-MSCs (Figure 7A).
Histological analysis of the adductor muscle of the ‘‘rescued’’
limbs revealed extensive muscle degeneration and pronounced
interstitial fibrosis in the HGPS–MSC group. The N-MSCmice, in
contrast, exhibited significantly less fibrosis and more muscle
regeneration (Figure S4).
The simplest explanation for limb salvage was a restoration of
blood flow following transplantation. To monitor blood flow after
MSC transplantation, laser Doppler imaging was performed at
days 0, 14, and 28 after surgery. The N-MSC-treated animals
had significantly improved blood flow in contrast to the HGPS
and culture medium groups (p < 0.001) (Figure 7B). Histological
examination for the presence of human cells in the affected limbs
by human nuclear antigen staining indicated that HGPS-MSC
disappear much faster than N-MSC in ischemia limbs. At day
35 after surgery, while some HNA positive cells could be seen
in N-MSCs transplanted samples, no positive cells were found
in HGPS-MSC treated limbs (Figure 7C).
MSC-mediated, postischemia recovery is attributed to neo-
vasculogenesis due to the secretion of paracrine factors by the
transplanted MSCs (Horwitz and Prather, 2009). However,
analysis of media conditioned by the various control and
HGPS-MSC preparations failed to reveal any differences in the
levels of those factors often implicated in neovasculogenesis
including VEGF, bFGF, and IL-6 (Figure S5A). We conclude
that the poor survival of HGPS-MSCs in ischemic limbs may
underlie limb-rescue failure.
MSCs in vivo occupy low oxygen niches and normally exhibit
a faster and longer proliferation potential under hypoxic condi-
tions (Dos Santos et al., 2010; Rosova et al., 2008). To determine(D) Immunostaining of progerin, LMNA, LAP2, and H2AX showed increased numb
VSMCs at p3. The percentage of cells showing abnormal phenotypes is indicatewhether HGPS-MSC loss is due to an acquired sensitivity to
ischemia-induced hypoxic conditions, we subjected the cells
to hypoxia and substratum deprivation as described earlier.
Under normal growth conditions, HGPS-MSC and N-MSCs
proliferated at same rate; however, after the hypoxia, only 40%
of the HGPS-MSCs survived compared to 80% of the N-MSCs
(Figure 6A). TUNEL assay showed that double the number of
HGPS-MSCs were apoptotic (Figure 7D). In parallel experi-
ments, HGPS fibroblasts and endothelial cells and their normal
controls derived from iPSCs survived, as well as human bone
marrow MSCs after hypoxia and substrate deprivation (Fig-
ure 6A). These results indicate that HGPS-MSCs are more sensi-
tive to the combination of hypoxia and substrate deprivation.
Interestingly, with hypoxia alone (3 days in 2% O2), very little
sensescence was noted in HGPS- and N-MSC populations in
contrast to the higher levels in HGPS-VSMCs (Figure 6B).
Antisense morpholinos or shRNAs specifically target and
suppress progerin expression (Huang et al., 2005). To demon-
strate that the increased sensitivity of the HGPS-MSCs were
a consequence of progerin expression, we infected N- or
HGPS-MSCs with lentiviral vectors expressing control shRNA
and shRNA against progerin. Resistance to hypoxia and
substratum deprivation is restored in HGPS-MSCs, when pro-
gerin levels were reduced by 65% (Figure 7E and Figure S6),
indicating progerin accumulation is responsible for this defect.
Finally, we determined if HGPS-MSCs were susceptible to
other forms of stress. Both HGPS-MSC and N-MSCs were
cultured in serum-free medium for 10 days. HGPS-MSC
numbers declined rapidly; in contrast, N-MSCs and adult bone
marrow MSCs survived serum starvation (Figure 7F).
In summary, HGPS fibroblasts, -MSCs, and -VSMCs all
display enhanced DNA damage, LAP2 mislocalization, and
pronounced nuclear dysmorphology. When exposed to addi-
tional stress in vitro and (MSC) in vivo, the viability of VSMCs
and MSCs were significantly reduced, with VSMCs showing
a particular sensitivity to low oxygen.
DISCUSSION
Mutations in LMNA are responsible for more than ten distinct
diseases (Mounkes and Stewart, 2004). HGPS is the best known
of these laminopathies, with the most common form of HGPS
being characterized by the production of the mutant lamin A,
progerin. It is widely believed that the pathological effects of
progerin aremediated by its disruption of the structural and func-
tional integrity of the nuclear lamina. Autopsies indicated that
death is associated with premature atherosclerosis (Olive
et al., 2010), which may be accompanied by vascular smooth
muscle loss (Stehbens et al., 2001) The limited biopsy data avail-
able shows progerin is mainly detected in some keratinocytes,
vascular smooth muscle, dermal fibroblast, and endothelial cells
(McClintock et al., 2006; Olive et al., 2010). Apart from the patient
data, most information on the disease pathophysiology has been
inferred from mouse models expressing mutated endogenous
LMNA alleles or mutated human or mouse LMNA transgenes,er of cells associated with mislocalization of LAP2 and DNA damage in HGPS-
d. Scale bar, 20 mm.
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Figure 6. Stress Testing of iPSC-Derived Lineages in Culture
(A) Cell survival rate after treatment with oil immersion and substrate deprivation. Values represent ratio of surviving cells relative to input. Results were obtained
from three biological replicates, and experiments were repeated three times. *p < 0.01 compared with controls in left panel, e.g., BM-MSC, N1-iPSC-MSC,
N2-iPSC-MSC, HUVEC, N1-iPSC-endo, N2-iPSC-endo, N1-VSMC, and N2-VSMC.
(B) Hypoxia treatment of VSMCs. Cells were incubated in 2% O2 with normal culture medium for 72 hr. Representative phase contrast and immunostaining
images show morphology of VSMC and LMNA staining. Cell senescence was detected by b-gal staining. The percentage of cells showing b-gal positive and
abnormal nuclei is indicated. Cell senescence is not observed in iPS-MSCs under the same treatment.
(C) Electrical stimulation of VSMCs. Electrical pulses (40V/cm, 1Hz) were applied to VSMCs in culture for a period of 3 days. Increased nuclear dysmorphology by
LMNA staining was observed in HGPS-VSMCs (left panel). Accelerated sensescence of HGPS-VSMCs was detected by b-gal staining (right panel). Experiment
was repeated, and *p < 0.01 compared with N-iPSC-VSMCs.
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Progeria iPSC Model Reveals MSC and VSMC Defectsstudies on cultured patient fibroblasts, or through overexpres-
sion of progerin in primary and immortalized human cells.
Although some mouse models with LMNA changes show
a severe HGPS-like growth retardation and bone disease
(Fong et al., 2004; Mounkes et al., 2003; Varga et al., 2006;40 Cell Stem Cell 8, 31–45, January 7, 2011 ª2011 Elsevier Inc.Yang et al., 2005), no mouse model captures all the human
symptoms and, until recently, only one (Varga et al., 2006)
displays a cardiovascular phenotype. Hernandez et al. (2010)
showed in the murine progeria model (LmnaD9/D9) that,
although the mutant lamin A in this strain has a different internal
Cell Stem Cell
Progeria iPSC Model Reveals MSC and VSMC Defectsdeletion to the one found in progerin, it retains a farnesylated tail,
resulting in number of characteristic progeric pathologies,
including thinning of the VSMC intima. These pathologies were
attributed inter alia to defective extracellular matrix synthesis.
Microarray comparisons of the HGPS and control iPSC-MSCs
indicated significant misregulation of transcripts encoding extra-
cellular matrix proteins, as previously reported by Csoka et al.
(2004) and Scaffidi and Misteli (2008), although we could not
detect the alteration in the named components of the Notch
signaling pathway reported by these latter authors (Table S3).
HGPS fibroblasts demonstrate increased nuclear blebbing,
mislocalization of the nuclear protein (LAP2), DNA damage,
and aberrant chromatin modifications in HGPS cells at late
passage as reported for. HGPS fibroblasts or MSCs expressing
exogenously added progerin genes (Scaffidi and Misteli, 2008).
Apart from fibroblasts, very few other patient-derived cell
lineages are available for study. Here, we describe an approach
to HGPS modeling that should, in time, allow the production and
investigation of multiple HGPS cell lineages with endogenous
levels of progerin and other lamins.
HGPS fibroblasts were reprogrammed to iPSC by retroviral-
mediated integration of the Yamanaka factors OCT4, SOX2,
KLF4, and C-MYC (Takahashi et al., 2007). Though the reprog-
ramming efficiency is low compared with normal fibroblasts,
the HGPS-iPSCs, once established, were all karyotypically
normal and indistinguishable from normal iPSCs and human
ESCs in many aspects, including specific marker expression,
germ layer formation, epigenetic status, and global transcrip-
tional expression. As expected for pluripotent cell types (Con-
stantinescu et al., 2006), very little progerin, lamin A, or lamin C
were detected in the undifferentiated iPSCs. Upon differentiation
into fibroblasts, neural progenitors, vascular endothelial cells,
VSMCs, andMSCs, the LMNA gene is transcriptionally activated
and progerin levels increase. We observed the highest levels of
progerin (and the highest levels of DNA damage, LAP2 mislocal-
ization, and nuclear dysmorphology) in HGPS-iPSC derived
MSCs, VSMCs, and fibroblasts, slightly less in endothelial cells
and very little in neural progenitors. These differences are likely
to reflect inherent variation in the production and/or turnover of
progerin in the different cell types and the relationship between
progerin level and damage may, if extended over many more
cell types, track the more affected tissues in HGPS patients.
Progerin did not affect either the efficiency of differentiation of
iPSCs into MSCs, VSMCs, endothelial cells, and neural progen-
itors, or the proliferation rate of these cell types. It did not func-
tionally interfere with lattice formation or LDL uptake in the endo-
thelial cells, or with neuron formation from the neural progenitors.
We also noticed a new and completely unexpected phenotype in
many of the HGPS-VSMCs: the appearance of heterogeneously
sized, calponin 1-staining inclusion bodies in the cytoplasm
(Figure 5). Calponin1 is an actin-binding protein involved in the
regulation of smooth muscle contraction, possibly by inhibiting
actin-activated myosin ATP-ase activity (Takahashi and Yama-
mura, 2003). We speculate that its sequestration into aggregates
could affect the contractile properties of the VSMC in situ.
HGPS-VSMCs were also very sensitive to 2% hypoxia and to
the combination of hypoxia and substratum deprivation. Further-
more, whenHGPS-VSMCswere subjected to repeated pulses of
electrical stimulation, they rapidly senesced; in the context of thevascular system, electrical stimulation has been used to
enhance angiogenesis (Zhao et al., 2004), to improve engineered
myocardium (Radisic et al., 2004) and, in this study, to act as
a surrogate means of mimicking the hemodynamic shear stress
normally endured by VSMCs in vivo. This pronounced sensitivity
of the HGPS-VSMCs to various imposed insults, as well as the
possible perturbation of contractile properties due to calponin
sequestration, may explain why this lineage features prominently
in the pathology of progeria.
HGPS and control iPSC-MSCs were differentiated into bone,
cartilage, and fat. We could not determine whether the efficiency
of differentiation into the various lineages was affected by the
presence of progerin, unlike Scaffidi and Misteli (2008), who
reported that adipogenesis was impaired while osteogenesis
was stimulated by progerin. We did not note any impact of pro-
gerin on adipogenesis, although osteogenenic differentiation
varied, but not in a progerin-specific manner (Figure 4E).
However, we believe the two sets of experiments are not compa-
rable since Scaffidi and Misteli (2008) obtained their results by
manipulation of a single MSC genotype, while each iPSC-MSC
population used in our study represented a different genotype,
and it is known that human MSC differentiation is influenced by
donor genotype (Leskela et al., 2006). We, therefore, elected to
functionally test iPSC-MSCs in vivo. Using a hind limb ligation
mouse model that measures limb survival and the restoration
of blood flow after cell transplantation, we found that HGPS-
MSCs were only slightly better than the vehicle in saving the
ischemic limb, in contrast to the successful rescue mediated
by control iPSC-MSCs or adult bone marrow MSCs. Microarray
comparisons between HGPS-MSCs and control MSCs showed
no obvious change in angiogenic factors such as VEGF, bFGF,
and Il-6, results confirmed by direct analysis of conditioned
media (Figure S5A). The histology of salvaged limbs showed
no long-term integration of any of the transplanted populations
and that HGPS-MSCs were cleared more rapidly than control
cells. We speculate that the HGPS-MSCs are cleared before
they can exert any trophic effect on the neighboring tissues.
This rapid clearance could reflect a greater sensitivity of HGPS-
MSCs to the ischemic conditions or to stress in general. Accord-
ingly, we stressed the cells in two ways: first, we studied their
reaction to serum starvation and found the HGPS-MSC numbers
rapidly declined (Figure 7F) and second, we deprived cells of
oxygen and substratum (Weil et al., 2009). Compared to the
control cells, survival of the HGPS-MSCs was significantly
reduced, an effect that was mostly reversed by a 65% decrease
in cellular progerin as a result of specific shRNA knockdown.We,
therefore, conclude that HGPS-MSC are particularly sensitive to
this type of hypoxic condition and believe that this is a significant
finding because MSCs normally reside in low O2 niches within
the body (Rosova et al., 2008). We do not yet have a molecular
explanation for this difference; transcript levels of one obvious
candidate-Hypoxia-Inducing Factor 1 were similar in control
and HGPS-MSCs, at least under normoxic conditions (Fig-
ure S5B). In vivo, the exact roles of MSCs are unclear, although
they may be a source of VSMCs and pericytes, but it is generally
agreed that they are important for tissuemaintenance and repair.
One hypothesis, for the underlying pathology of HGPS, is that
progerin inhibits cell replacement in the cardiovascular system,
hair follicles, fat, and cartilage due to premature exhaustion ofCell Stem Cell 8, 31–45, January 7, 2011 ª2011 Elsevier Inc. 41
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Figure 7. Rescue of Ischemic Murine Hind Limb Using Transplanted iPSC-Derived MSCs
(A) Transplantation of HGPS-iPSC-MSCs failed to attenuate hind-limb ischemia. At day 28 after transplantation of bonemarrow or iPSC-derivedMSCs, the phys-
iological status of ischemic limbs were rated for limb salvage, foot necrosis, and limb loss. The BM-MSC (p = 0.0058) and N-iPSC-MSC (p = 0.0092), but not
HGPS-iPSC-MSC (p = 0.2779), showed significant rescue of ischemia. Student’s t test (two tail) comparison with vehicle is used for analysis (n = 8 for vehicle,
n = 15 per group).
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Progeria iPSC Model Reveals MSC and VSMC Defectsstem cell pools (Halaschek-Wiener and Brooks-Wilson, 2007),
perhaps by inhibiting Wnt signaling (Hernandez et al., 2010;
Meshorer and Gruenbaum, 2008). Our findings lead us to
propose a refinement to their model and suggest that in addition
to the ‘‘exhaustion’’ caused by the need to replace lost mesen-
chymal tissue, the MSC pool is also depopulated due to
increased hypoxia sensitivity caused by progerin. Given the
historical (Horwitz and Prather, 2009) and current clinical trials
(http://clinicaltrials.gov/ct2/show/NCT01061099) using alloge-
neic MSCs for another congenital disease, osteogenesis imper-
fecta, our data suggest MSCs may be of therapeutic use for
HGPS patients.
To our knowledge, this is the first report of an iPSC-based
disease model of HGPS. It complements existing approaches
using animal and cell models, and the achievement of tissue-
specific expression of a disease-associated gene at endoge-
nous levels must be considered an attractive feature. This
general approach is still young and faces numerous challenges,
particularly regarding the appropriateness of using embryonic
starting material to model neonatal and adult onset diseases
(Colman and Dreesen, 2009; Saha and Jaenisch, 2009). We
are encouraged by the demonstration that the HGPS-iPSCs
can yield distinctive phenotypes, e.g., VSMCs and MSCs, that
lead to specific predictions that could be tested with suitable
animal and cellular models and/or patient material.
EXPERIMENTAL PROCEDURES
Cell Culture
HGPS patient fibroblast cells, adult human bone marrowMSCs, human umbil-
ical cord endothelial cells (HUVECs), and the human neural stem cell line (ReN-
cells) were purchased from Coriell cell repositories (http://ccr.coriell.org/),
Lonza, and Millipore, respectively. Fetal bone marrow MSC was obtained
from S.K. Lim (Institute of Medical Biology, Singapore). All cell cultures were
maintained at 37C with 5% CO2. Human embryonic stem cell lines (hESCs)
HES3, H9, and induced pluripotent stem cells (iPSCs) were cultured on irradi-
ated mouse embryonic fibroblasts (MEFs) with Knockout DMEMmedium sup-
plemented with 20% knockout serum replacement, nonessential amino acid,
2-mercaptoethanol, penicillin/streptomycin, GlutaMax, and bFGF. Cells were
passaged with collagenase IV (all GIBCO). The hypoxia and substrate depriva-
tion assay was performed according to Weil et al. (2009). Cells were harvested
using 0.25% Trypsin-EDTA and pelleted by centrifugation. 3 3 105 cells were(B) The dynamic change of blood flow after MSC transplantation. Hind limb ischem
was used as control for blood flow measurement using laser Doppler flow imagin
and restoration of blood flow 28 days after MSC transplantation (right panel). Rest
lower than N-iPSC-MSC group at 4 weeks. (p < 0.001, n = 15 per group). Three
patient fibroblasts were used to derive the MSCs used for transplantation.
(C) Immunostaining of human nuclear antigen (HNA) in ischemic limb tissues. Mic
immunostaining using antibody against HNA. Human cells stained brown (red ar
5 weeks. Scale bar, 200 mm.
(D) Percentage of cell death after hypoxia and substrate deprivation treatment. Ap
analyzed by FACS. Results were each obtained from three biological replicates
iPSC-MSC/PG2-iPSC-MSC (p < 0.01).
(E) Knocking down progerin in HGPS-iPSC-MSC improves survival in hypoxia and
shRNAs before being challenged. Values represent ratio of surviving cells relativ
ments were repeated two times. *p < 0.01 compared with H9-derived MSC, N
expressing control shRNA), and PG1-shD50 (HGPS-iPSC-MSC expressing shRN
(F) Cell proliferation in serum-free medium. HGPS or control iPSC-derived MSCs
for each line and cell survival wasmeasured using aWST-1 kit (Roche) according t
with three normal control groups.
See also Figure S4 for representative images of fibrosis in hind limbs of ischemic m
progerin shRNA and lamin expression.exposed to 2–4 hr of hypoxia via mineral oil immersion followed by reoxygena-
tion in normal conditions for 24 hr. Surviving cells were counted using Trypan
blue stain.
Retroviral Production and iPS Generation
The pMX-based retroviral vector encoding the human cDNAs of KLF4, SOX2,
OCT4, and C-MYCwere obtained from Addgene. Retrovirus was produced as
described (Dimos et al., 2008). Briefly, pMXs plasmids were cotransfectedwith
packaging plasmid gag-pol and VSV-G into 293T packaging cells (ATCC)
using SuperFect (QIAGEN). Viral supernatant fractions were harvested after
60 hr, filtered through a 0.45 mm low protein binding cellulose acetate filter,
and concentrated by centrifugation. To produce patient-specific iPSCs, two
rounds of viral transduction of 100,000 fibroblast cells were performed. After
4 days, cells were transferred onto MEFs in human ESC medium containing
0.5 mM valproic acid (VPA, Sigma). iPSC colonies were manually picked after
2 to 3 weeks.
Differentiation of iPSCs into Fibroblast-like Cells
The human ESCs and iPSCs were harvested using collagenase IV and
embryoid bodies (EBs) were formed and transferred to gelatin-coated plates
in differentiation medium as described (Xu et al., 2004). The cells were subse-
quently passagedwithmedium containing 90%DMEM (Invitrogen), 10%heat-
inactivated FBS (Hyclone), 2mM L-glutamine, and 1% nonessential amino
acids. Cells were further purified with Thy1 antibody by FACS sorter. The iden-
tity of the established fibroblast-like cells was confirmed with immunostaining
by antibody against human fibroblast/epithelial cells (Novus Biologicals,
D7-FIB) and prolyl4-hydroxylase, an enzyme required for collagen synthesis.
Differentiation of VSMCs from MSCs
VSMCs were differentiated from iPSC-MSCs by culturing in EGM-2 medium
(Lonza) with sphingosylphosphorylcholine (SPC, 5 mM) and TGFb1 (2 ng/ml)
for 3 weeks. The identity of VSMCs was verified by specific marker expression
of smooth muscle actin, smooth muscle myosin heavy chain and calponin by
RT-PCR and immune-staining (all DAKO 1:100). Contraction of VSMCs was
induced by carbachol at 13 105 M for 1 hr. Electrical stimulation was applied
to VSMCs using C-pace/C-dish cell culture stimulation system (IonOptix, MA)
at 40V, 1 Hz with pulse duration of 2 ms.
Knockdown of Progerin in HGPS-iPS-MSCs by Lentiviral Infection
ShRNA-specific knockdown of lamin AD50 (progerin), but not lamin A or C,
was designed according to Huang et al. (2005). Oligonucleotides encoding
the hairpin shRNA (shD50) targeting the sequence (50-GGC TCA GGA GCC
CAG AGC CCC-30) were cloned into the lentiviral vector plko.3G (Addgene).
A shRNA that does not target any mammalian gene (50-TTC TCC GAA CGT
GTC ACGT-30) was used as control (shcon). For lentivirus production, lentiviral
vectors were cotransfected with packaging vectors into 293FT cells, and theia was created by ligation of the left hind limb femoral artery. The right hind limb
g. Representative Doppler photo shows no blood flow upon ligation (left panel)
oration of blood flow in the HGPS-iPSC-MSC transplanted group is significantly
iPSC clones (PG1-iPSC-1, PG1-iPSC-2, and PG2-iPSC-1) from two different
e tissues were paraformaldehyde fixed, paraffin embedded, and sectioned for
row) were not found anywhere in HGPS-iPSC-MSC transplanted tissues after
optotic cells were label by TUNEL (TdT-mediated dUTP nick end labeling) and
. N1-iPSC-MSC/N2-iPSC-MSC shows significantly more resistant than PG1-
substrate deprivation assay. Cells were transfected with lentivirus-containing
e to input. Results were obtained from three biological replicates, and experi-
1-NTC (N1-iPSC-MSC Non-Transduction Control), N1-shcon (N1-iPSC-MSC
A against progerin).
or bone marrow MSCs were seeded at a density of 43 104 per well in triplicate
o themanufacturer’s protocol. Value representsmean ± SD *p < 0.01 compared
ice, Figure S5 for characterization of hypoxia related factors, and Figure S6 for
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at 25,000 r.p.m. in a Beckman SW28 rotor. Titers were determined by infecting
NIH/3T3 cells with a serial dilution of the concentrated virus. For a typical prep-
aration, the titer was approximately 1–53 107/ml. 23 105 cells were incubated
in suspension with 1 3 106 particles and 8 mg/ml polybrene for 3 hr in a 37C
incubator. The cells were then replated and cultured as described. GFP-posi-
tive cells were sorted after 4 days of culture.
Limb Ischemia and Transplantation Studies
SCID mice were anesthetized with xylazine (20 mg/kg) and ketamine
(100 mg/kg), and critical limb ischemia was induced as described previously
(Lian et al., 2010). The femoral artery and its branches were ligated through
a skin incision with 5-0 silk (Ethicon, Somerville, NJ). The external iliac artery
and all of the above arteries were then ligated. The femoral artery was excised
from its proximal origin as a branch of the external iliac artery to the distal point
where it bifurcates into the saphenous and poplite arteries. After arterial liga-
tion, SCID mice were immediately assigned to the following experimental
groups: (1) N-iPS-MSC group: the mice were injected with MSCs derived
from normal control iPSCs (3.0 3 106 cells per mouse in 200 mL) intramuscu-
larly at four sites of the gracilis muscle in the medial thigh with 29-gauge tuber-
culin syringes; (2) PG- iPS-MSC: the mice were injected as above with MSCs
derived from HGPS patient iPSCs. Fetal bone marrow (BM)-MSC and culture
medium (vehicle) were used as controls. To exclude the possibility of bacterial
infection following surgery being responsible for poor recovery, specimens of
the ischemic muscle were cultured on day 7 after surgery and no bacterial
growth was detected in each group. All animal experiments were approved
by Committee on the Use of Live Animals in Teaching and Research (CULTAR)
at the University of Hong Kong.
Laser Doppler Imaging Analysis
Laser Doppler imaging analysis was performed as described previously (Lian
et al., 2010). A laser Doppler perfusion imager (Moor Instruments, Devon,
United Kingdom) was used for serial scanning of surface blood flow of hind-
limbs on days 0, 7, 14, and 28 after treatment. The digital color-coded images
were analyzed to quantify the blood flow in the region from the knee joint to the
toe, and mean values of perfusion were calculated.
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